title: Effect and Safety of Recombinant Adenovirus-p53 Transfer Combined with Radiotherapy on Long-Term Survival of Locally Advanced Cervical Cancer.
abstract: Detection of exogenous p53 gene and target gene expression in cervical cancer cell lines SiHa and C33A infected by recombinant adenovirus-p53 (rAd-p53) in vitro. The rAd-p53 infection evidently increased the expression of exogenous p53 gene, p21 gene, and Bax gene. The radiosensitization rates of rAd-p53 were 1.19 in SiHa and 1.18 in C33A in vitro. To evaluate the effect and safety of rAd-p53 transfer combined with radiotherapy (RT) in patients with cervical cancer, rAd-p53 transfer combined with radiotherapy (group PRT) in 69 patients with cervical cancer was compared with a control group treated with radiotherapy alone (group RT) in 35 patients with cervical cancer. Patients were intratumorally injected with rAd-p53 (1 × 1012virus particles) once a week for 6 weeks. Concurrent pelvic RT plus brachytherapy to take point A to 76.0 Gray units (Gy) (range 75-80 Gy). The 5-year overall survival rate of the PRT group was 17.5% higher than that of the RT group (HR = 0.551, 95% CI 0.278-1.095, p = 0.084). The 5-year progress-free survival rate of the PRT group was 17.1% higher than that of the RT group (HR = 0.485, 95% CI 0.234-1.006, p = 0.047). rAd-p53 administration did not increase the adverse events caused by radiotherapy, except for transient fever after rAd-p53 administration. rAd-p53 was safe and biologically active in improving radiotherapeutic survival rates in patients with cervical cancer.
authors: 1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Departure of Radiotherapy, Peking University Cancer Hospital and Institute , Beijing, China .
authors: Xing
authors: X
authors: Su
authors: 2 Fujian Province Cancer Hospital , Fuzhou, China .
authors: Wen-Juan
authors: WJ
authors: Chen
authors: 1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Departure of Radiotherapy, Peking University Cancer Hospital and Institute , Beijing, China .
authors: Shao-Wen
authors: SW
authors: Xiao
authors: 1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Departure of Radiotherapy, Peking University Cancer Hospital and Institute , Beijing, China .
authors: Xiao-Fan
authors: XF
authors: Li
authors: 1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Departure of Radiotherapy, Peking University Cancer Hospital and Institute , Beijing, China .
authors: Gang
authors: G
authors: Xu
authors: 2 Fujian Province Cancer Hospital , Fuzhou, China .
authors: Jian-Ji
authors: JJ
authors: Pan
authors: 1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Departure of Radiotherapy, Peking University Cancer Hospital and Institute , Beijing, China .
authors: Shan-Wen
authors: SW
authors: Zhang
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000401:mortality* / Q000532:radiotherapy / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000008:administration & dosage*; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage; D011993:Recombinant Fusion Proteins / Q000235:genetics; D012449:Safety; D015996:Survival Rate; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*; D002583:Uterine Cervical Neoplasms / Q000401:mortality* / Q000532:radiotherapy / Q000628:therapy
chemical_list: D011838:Radiation-Sensitizing Agents; D011993:Recombinant Fusion Proteins; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
keywords: cervical cancer; radiotherapy; recombinant adenovirus-p53